Although at lower frequencies than observed in hematological malignancies, TET2 alterations have also been found in various types of solid tumors, such as renal cell carcinoma [44], metastatic castration-resistant prostate cancer (mCRPC) [45], lung [46], colon and rectal cancer [47]. This evidence concerns the gene TET2 and renal cell carcinoma.